Loading…
Loading…
VKTX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VKTX and 80,000+ other tickers.
See exactly how VKTX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VKTX and 80,000+ other tickers.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal…
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs.
The key trial results for VK2735 are still years away. There are some useful indicative results coming from a phase 1 maintenance trial over the next six or so months.
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $37.08, representing a +1.95% change from its previous close.
VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.